gms | German Medical Science

78th Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

German Society of Oto-Rhino-Laryngology, Head and Neck Surgery

16.05. - 20.05.2007, Munich

Bortezomib - a new approach in head & neck cancer therapy

Meeting Abstract

German Society of Oto-Rhino-Laryngology, Head and Neck Surgery. 78th Annual Meeting of the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery. Munich, 16.-20.05.2007. Düsseldorf, Köln: German Medical Science; 2007. Doc07hno090

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/hno2007/07hno090.shtml

Published: August 8, 2007

© 2007 Wagenblast et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Proteasome inhibition has been shown to be an effective anticancer agent in the treatment of multiple myeloma disease as well as in solid tumors.

We investigated the antitumoral effects of Bortezomib in SCCHN cell lines and furthermore sought to identify drug interactions between Bortezomib, Docetaxel and Cisplatin (CDDP).

Eight different SCCHN cell lines were treated with descending doses of Docetaxel, CDDP or Bortezomib alone and with Docetaxel or CDDP each in combination with Bortezomib .

Apoptosis and cell viability were detected by cytohistology to quantitate drug effects.

Bortezomib as single used drug shows a remarkable anticancer effect in SCCHN cell lines but also in combination with Docetaxel or CDDP by inducing apoptosis and thus cell death.

Our results further suppose adding Bortezomib to Docetaxel-or CDDP -Regime may improve Docetaxel-/CDDP treatment intensifying antiproliferative effects.

Bortezomib and Docetaxel-/CDDP-Regime represent an additive drug combination that warrants further evaluation in in- vivo models of head and neck cancer.